Last updated: February 16, 2026
Overview
NDC 00121-1744 corresponds to Xarelto (rivaroxaban), an oral anticoagulant developed by Bayer and prescribed primarily for stroke prevention in atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). Recent market trends, patent status, competition, and regulatory factors shape the revenue potential and pricing strategies for this drug.
Market Size and Growth
Global Market Value:
The global anticoagulant market was valued at approximately $8.96 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of around 7% through 2028, reaching nearly $13.7 billion. The growth is driven by aging populations, increased prevalence of atrial fibrillation, and shift from vitamin K antagonists to direct oral anticoagulants (DOACs) ([1]).
US Market:
In the United States, the anticoagulant segment generated over $3 billion in sales in 2022. Xarelto accounts for roughly 35-40% of the market share within DOACs, securing annual sales near $1.4 billion in the US alone.
Key Indications and Patient Demographics:
- Atrial fibrillation: ~5 million patients in the US, projected to grow
- DVT/PE treatment and prevention: high recurrence rates and broad use in surgical prophylaxis
- Off-label uses include prophylaxis in other surgical procedures
Competitive Landscape
Major Competitors:
- Eliquis (apixaban): Holds approximately 30% of US DOAC market, with comparable approvals for AFib, DVT, PE
- Dabigatran (Pradaxa): Approximate 10-15% market share, with less favorable dosing profile
- Warfarin: Declined, but still accounted for a significant share due to lower cost and established use
Market Share Dynamics:
Xarelto maintains a leading position due to patent exclusivity until 2024, established efficacy, and broad indications. However, patent expirations threaten pricing power post-2024, encouraging competitive pricing and biosimilar development.
Patent and Regulatory Status
- Xarelto’s primary patent protection expired in the US in 2024; secondary patents may extend exclusivity in some jurisdictions until 2027.
- Pending biosimilar and generic entries are potential threats, likely to enter the market at 40-60% of current pricing levels ([2]).
Pricing Trends and Projections
Current Pricing:
- Brand Xarelto: Approximately $500-$600 for a 30-day supply
- Generic/biosimilar versions: Priced at 40-60% lower, around $250-$350 for equivalent supply
Price Decline Forecast (Post-Patent):
- Expect a 35-50% reduction in average wholesale price (AWP) within 2 years of patent expiry, driven by biosimilar entries and market competition ([3]).
Market Penetration Strategy Impact:
- Payers and providers favor generic/pill-sharing options, decreasing Xarelto’s premium price.
- Price erosion could pressure revenues, especially in crowded indications like atrial fibrillation.
Revenue Projections (2023-2028)
| Year |
Estimated US Sales |
Global Revenue |
Assumptions |
| 2023 |
$1.2 billion |
$2.8 billion |
Market still brand-dominant; patent impact begins |
| 2024 |
$900 million |
$2.3 billion |
Patent expiry; biosimilars introduced in the US |
| 2025 |
$700 million |
$2.0 billion |
Increased biosimilar competition; price declines |
| 2026 |
$600 million |
$1.8 billion |
Market share shifts to generics; off-label use declines |
| 2027 |
$500 million |
$1.6 billion |
Biosimilar dominance; pricing stabilization |
Note: Estimates assume conservative biosimilar penetration; actual figures depend on regulatory approvals, market acceptance, and pricing strategies.
Regulatory and Market Access Factors
- Reimbursement policies in the US favor generics, lowering barriers to biosimilar entry.
- In emerging markets, brand Xarelto maintains premium pricing due to local regulatory and patent protections.
- Payer negotiations and formulary placements significantly influence actual sale prices.
Key Takeaways
- Xarelto (NDC 00121-1744) dominates the anticoagulant segment with substantial revenues, primarily in the US and Europe.
- Patent expiration likely to cause marked price reduction and revenue decline beginning in 2024.
- Biosimilars and generics will exert downward pressure, with price drops of up to 50% expected within two years post-expiry.
- New indications or approved formulations may temporarily bolster sales but are unlikely to offset patent losses.
- Competitive dynamics and healthcare policy reforms continue to shape pricing and market access.
FAQs
1. When does Xarelto’s patent expire?
Patent protections in the US expired in 2024, with some secondary patents potentially extending exclusivity until 2027.
2. How will biosimilar competition affect Xarelto’s market share?
Biosimilars are expected to capture 50-70% of the market within 2-3 years of entry, driving prices down substantially.
3. What prices are expected for Xarelto post-patent expiration?
Average wholesale prices could fall by 40-50%, with generics priced approximately $250-$350 per month.
4. Which markets offer the highest growth potential for Xarelto?
Emerging markets with increasing adoption of direct oral anticoagulants and expanding healthcare infrastructure.
5. What are the key risks to Xarelto’s revenue forecast?
Regulatory delays for biosimilars, payer resistance to high prices, off-label use restrictions, and competing therapies.
References
[1] MarketWatch, "Anticoagulant Market Size & Trends," 2022.
[2] FDA, "Biosimilar and Generic Drug Approvals," 2023.
[3] EvaluatePharma, "Pricing and Patent Impact," 2022.
